Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Lantheus Holdings, Inc. has received a consensus rating of "Moderate Buy" from analysts, with two hold and five buy ratings, and an average one-year price target of $105.50.
• Insider Rajiv A. Patel sold over 3.36 million shares at an average price of $56.15, reducing his stake in the company by nearly 49.18%.
• The company reported $1.57 earnings per share for the last quarter, missing analysts' expectations of $1.65, with a year-over-year revenue decline of 4.1%.

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $105.50.

A number of research analysts have recently commented on the stock. William Blair reaffirmed a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Truist Financial set a $63.00 price objective on shares of Lantheus and gave the company a "hold" rating in a research note on Monday, August 11th. Mizuho dropped their price objective on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. Finally, JMP Securities dropped their target price on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a research report on Thursday, August 7th.

Insiders Place Their Bets

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the transaction, the director owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,838,066 shares of company stock worth $384,430,031 in the last 90 days. 2.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Lantheus

Several large investors have recently added to or reduced their stakes in LNTH. State of Michigan Retirement System boosted its stake in Lantheus by 0.6% during the first quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider's stock valued at $1,620,000 after buying an additional 100 shares in the last quarter. Signaturefd LLC boosted its stake in Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 116 shares in the last quarter. Intrust Bank NA boosted its stake in Lantheus by 2.9% during the first quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider's stock valued at $431,000 after buying an additional 125 shares in the last quarter. Focus Financial Network Inc. boosted its stake in Lantheus by 4.0% during the second quarter. Focus Financial Network Inc. now owns 3,576 shares of the medical equipment provider's stock valued at $293,000 after buying an additional 136 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in Lantheus by 2.1% during the first quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider's stock valued at $653,000 after buying an additional 139 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Performance

Shares of Lantheus stock opened at $55.66 on Wednesday. The firm's fifty day simple moving average is $70.60 and its 200-day simple moving average is $83.77. The stock has a market capitalization of $3.78 billion, a price-to-earnings ratio of 14.80 and a beta of 0.14. Lantheus has a 12 month low of $47.25 and a 12 month high of $118.21. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). The firm had revenue of $378.05 million during the quarter, compared to analysts' expectations of $389.69 million. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business's quarterly revenue was down 4.1% on a year-over-year basis. During the same quarter last year, the business earned $1.80 earnings per share. As a group, equities analysts forecast that Lantheus will post 6.01 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.